Evaluation of the Efficacy and Safety of GS-5745 as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Subjects With Moderate to Severe Rheumatoid Arthritis

The primary objective of this study is to evaluate the efficacy of andecaliximab (GS-5745) versus placebo as an add-on therapy to a tumor necrosis factor (TNF) inhibitor and methotrexate in adults with moderate to severe rheumatoid arthritis (RA).

Start Date15 Dec 2016

Sponsor / Collaborator

Gilead Sciences, Inc.

NCT02759562 / TerminatedPhase 2

A Phase 2b, Dose-Ranging Study of the Effect of GS-5745 on FEV1 in Adult Subjects With Cystic Fibrosis

The primary objective of this study is to evaluate the effect of andecaliximab (GS-5745) on pre-bronchodilator forced expiratory volume in 1 second (FEV1) % predicted in adults with cystic fibrosis (CF) after 8 weeks of treatment.
There will be 2 parts to this study. In Part 1, andecaliximab 600 mg or placebo will be administered for 8 weeks. In Part 2, andecaliximab 300 mg, 150 mg, or placebo will be administered for 8 weeks. Part 2 will be initiated after completion of Part 1.

Start Date04 Nov 2016

Sponsor / Collaborator

Gilead Sciences, Inc.

CTRI/2016/09/007304 / TerminatedPhase 2/3

A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely Active Ulcerative Colitis

Start Date01 Nov 2016

Sponsor / Collaborator-

100 Clinical Results associated with Andecaliximab

100 Translational Medicine associated with Andecaliximab

100 Patents (Medical) associated with Andecaliximab

Literatures (Medical) associated with Andecaliximab

01 Jan 2024·International journal of medical sciences

Text Mining and Drug Discovery Analysis: A Comprehensive Approach to Investigate Diabetes-Induced Osteoporosis

Article

Author: Hu, Yihe ; Liang, Feng ; Wang, Chenfeng

Purpose: Osteoporosis (OP) and diabetes are prevalent diseases in orthopedic and endocrinology departments, with OP potentially arising as a complication of diabetes. However, the mechanism underlying diabetes-induced osteoporosis (DOP) remains enigmatic, and drug discovery in this domain is restricted, hindering research into the DOP's etiology and treatment. With the ultimate goal of preventing OP in diabetic patients, the objective of this study is to mine the genes and pathways linked to DOP using bioinformatics and databases. Method: The present study employed text mining as the initial approach to retrieve genes commonly associated with diabetes and OP. Subsequently, functional annotation was conducted to investigate the roles and functionalities. In order to explore the interactions between proteins relevant to DOP, we constructed protein-protein interaction (PPI) networks. Furthermore, to obtain key genes and candidate drugs for DOP treatment, we conducted drug-gene interaction (DGI) analysis, complemented by a thorough examination of transcriptional factors (TFs)-miRNA co-regulation. Results: The results through text mining revealed 110 genes that are commonly associated with both diabetes and OP. Subsequent enrichment analysis narrowed down the list to 95 symbols that were involved in PPI analysis. After DGI analysis, we identified 7 genes targeted by 11 drugs, which represent candidates for treating DOP. Conclusion: This study unveils ANDECALIXIMAB, SILTUXIMAB, OLOKIZUMAB, SECUKINUMAB, and IXEKIZUMAB as promising potential drugs for DOP treatment, demonstrating the significance of utilizing text mining and pathway analysis to investigate disease mechanisms and explore existing therapeutic options.

01 May 2023·Computers in biology and medicine

Identification of key genes in colorectal cancer diagnosis by weighted gene co-expression network analysis

Article

Author: Tapak, Leili ; Mortezapour, Mahdie ; Najafi, Rezvan ; Afshar, Saeid ; Bahreini, Fatemeh

BACKGROUND:

The purpose of this study was using bioinformatics tools to identify biomarkers and molecular factors involved in the diagnosis of colorectal cancer, which are effective for the diagnosis and treatment of the disease.

METHODS:

We determined differentially expressed genes (DEGs) related to colorectal cancer (CRC) using the data series retrieved from GEO database. Then the weighted gene co-expression network analysis (WGCNA) was conducted to explore co-expression modules related to CRC diagnosis. Next, the relationship between the integrated modules with clinical features such as the stage of CRC was evaluated. Other downstream analyses were performed on selected module genes.

RESULTS:

In this study, after performing the WGCNA method, a module named blue module which was more significantly associated with the CRC stage was selected for further evaluation. Afterward, the Protein-protein interaction network through sting software for 154 genes of the blue module was constructed and eight hub genes were identified through the evaluation of constructed network with Cytoscape. Among these eight hub genes, upregulation of MMP9, SERPINH1, COL1A2, COL5A2, COL1A1, SPARC, and COL5A1 in CRC was validated in other microarray and TCGA data. Based on the results of the mRNA-miRNA interaction network, SERPINH1 was found as a target gene of miR-940. Finally, results of the DGIDB database indicated that Andecaliximab, Carboxylated glucosamine, Marimastat, Tozuleristide, S-3304, Incyclinide, Curcumin, Prinomastat, Demethylwedelolactone, and Bevacizumab, could be used as a therapeutic agent for targeting the MMP9. Furthermore, Ocriplasmin and Collagenase clostridium histolyticum could target COL1A1, COL1A2, COL5A1, and COL5A2.

CONCLUSION:

Taken together, the results of the current study indicated that seven hub genes including COL1A2, COL5A1, COL5A2, SERPINH1, MMP9, SPARC, and COL1A1 which were upregulated in CRC could be used as a diagnostic and progression biomarker of CRC. On the other hand, miR-940 which targets SERPINH1 could be used as a potential biomarker of CRC. More ever, Andecaliximab, Carboxylated glucosamine, Marimastat, Tozuleristide, S-3304, Incyclinide, Curcumin, Prinomastat, Demethylwedelolactone, Bevacizumab, Ocriplasmin , and Collagenase clostridium histolyticum were introduced as therapeutic agents for CRC which their therapeutic potential should be evaluated experimentally.

01 Jan 2022·Journal for immunotherapy of cancerQ2 · MEDICINE

Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study

Q2 · MEDICINE

ArticleOA

Author: Zavodovskaya, Marianna ; Mitani, Seiichiro ; Yamaguchi, Kensei ; Ichimura, Takashi ; Liu, JieJane ; Kudo, Toshihiro ; Chin, Keisho ; Muro, Kei ; Satoh, Taroh ; Boku, Narikazu ; Yoshikawa, Akie Kimura ; Takashima, Atsuo ; Sakai, Daisuke ; Kadowaki, Shigenori ; Kitano, Shigehisa ; Thai, Dung

Background:

Matrix metalloproteinase 9 (MMP9) is implicated in protumorigenic processes. Targeting either stromal or epithelial MMP9 reduces the incidence of metastasis. Andecaliximab is a monoclonal antibody that targets MMP9 with high affinity and selectivity. However, no study has examined whether the inhibition of T-cell programmed death 1 (PD-1) in the presence of andecaliximab increases activated lymphocyte infiltration into the tumor, thereby increasing antitumor activity more than that in anti-PD-1 monotherapy. In this study, we assessed the safety, pharmacokinetics (PK), exploratory biomarkers, and preliminary efficacy of andecaliximab as monotherapy and in combination with nivolumab in Japanese patients with advanced or recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Methods:

This phase 1b study comprised four cohorts enrolling Japanese patients with gastric or GEJ adenocarcinoma. This paper concerns cohorts 1 and 4; cohorts 2 and 3 will be reported subsequently. Cohort 1 enrolled patients with human epidermal growth factor receptor 2 (HER2)-negative tumors (n=8) who received andecaliximab monotherapy (800 mg by intravenous infusion every 2 weeks (Q2W)), and cohort 4 enrolled patients irrespective of their HER2 status (n=10) who received 800 mg of andecaliximab in combination with nivolumab Q2W. Safety, dose-limiting toxicities (DLTs), PK, pharmacodynamics, and biomarkers were assessed in both cohorts.

Results:

PK of andecaliximab in Japanese patients with gastric or GEJ adenocarcinoma was similar to that reported in non-Japanese patients with advanced solid tumors. Andecaliximab monotherapy and in combination with nivolumab demonstrated no DLTs in cohort 1 and 4, respectively. Toxicities were manageable and well tolerated in both cohorts. The median progression-free survival was 1.4 months (90% CI, 0.5 to 5.4) and 4.6 months (90% CI, 0.9 to not reached) in cohorts 1 and 4, respectively. The objective response rate was 50% (90% CI, 22% to 78%) in cohort 4, and in some patients, the combination therapy was effective regardless of the biomarker status.

Conclusions:

The andecaliximab–nivolumab combination demonstrated a manageable safety profile and promising clinical activity in patients with advanced gastric adenocarcinoma.NCT02862535.

News (Medical) associated with Andecaliximab

21 Jun 2024

·www.biopharmadive.com

Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs

Today, a brief rundown of news from Jazz Pharma, Vanda Pharmaceuticals, ITM, Ashibio and Novartis that you might have missed from earlier in the week.An experimental medicine that Jazz Pharmaceuticals picked up in 2019 has failed a mid-stage study testing it against essential tremor. Researchers evaluated three doses of the medicine in 420 participants. They found the highest dose didn't meet the study's main or secondary goals, though there were “numeric improvements“ that hinted at some benefit. According to Jazz's research and development head, the company will wait for results from a separate trial focused on Parkinson's disease tremor before making a decision on next steps for the program. Those data are expected to come early next year. Jacob BellVanda Pharmaceuticals' board of directors on Thursday rejected two offers to acquire the company, determining that unsolicited bids from Cycle Group Holdings and Future Pak substantially undervalue the company. Cycle Group Holdings had proposed to acquire Vanda for $8.00 per share, while Future made a revised bid to buy the company for $8.50 to $9.00 per share in cash plus certain contingent value rights. Vanda shares have risen by 34% this year and now trade around $6 apiece. Delilah AlvaradoSteffen Schuster, CEO of radiopharmaceutical drug developer ITM, will step down from his position Sept.1 and move over to the companys supervisory board. He will be replaced by Andrew Cavey, who most recently was at Bristol Myers Squibb as an executive overseeing cancer cell therapy. Prior to Bristol Myers, Cavey was at Novartis, where he co-led the companys radiopharmaceutical strategy in prostate cancer. ITM recently raised $205 million. Ned PagliaruloAshibio emerged from stealth Thursday with $40 million in seed and Series A financing, the latter of which was led by MPM BioImpact. The funding will help the biotechnology company advance a new therapy for the rare genetic disorder fibrodysplasia ossificans progressiva, which gradually causes muscles and tendons to ossify into bone. Ashibio licensed from Gilead Sciences an antibody called andecaliximab that targets the MMP-9 gene, mutations in which appeared protective in a notable case study. The company plans to initiate a Phase 2/3 trial in the second half of 2024. Delilah AlvaradoNovartis intends to squeeze out the remaining minority shareholders of Morphosys who have not tendered their shares to the former companys acquisition of the German biotechnology firm. Novartis currently holds 91.04% of Morphosys total share capital and plans to transfer the remainder to itself for cash compensation. Novartis and Morphosys are also moving to delist the biotechs stock from the Frankfurt and Nasdaq stock exchanges. Ned Pagliarulo '

AcquisitionCell TherapyExecutive ChangeClinical Result

20 Jun 2024

·firstwordpharma.com

āshibio raises $40M to turn an ex-Gilead antibody into rare disease treatment

Six years after Gilead Sciences terminated a late-stage gastric cancer study of andecaliximab, the antibody is getting a new lease on life as an experimental treatment for a rare genetic disease.āshibio, helmed by Gilead’s former oncology therapeutic area head Pankaj Bhargava, emerged from stealth Thursday with $40 million in seed and series A financing to develop andecaliximab for fibrodysplasia ossificans progressiva (FOP), a disorder that causes extra-skeletal bone formation. The funds will help the biotech launch a Phase II/III trial of andecaliximab in patients with FOP next half. The antibody has been granted an orphan drug designation by both the FDA and European Medicines Agency.MPM BioImpact led the A round, with Agent Capital, YK Bioventures, and Mirae Asset Venture Investment also participating.Genetic rationaleWhile andecaliximab may have failed as a cancer treatment, āshibio believes the antibody has potential for FOP because a mutation in the gene that encodes its target – the matrix metalloproteinase-9 (MMP-9) enzyme – has been tied to an amelioration of the disease’s severe symptoms. Bhargava co-authored a paper, published February in the Journal of Bone and Mineral Research, that examined a 35-year-old patient with the genetic mutation for FOP, but had near-normal mobility and lacked the heterotopic ossification (HO) associated with the disease. The patient also had an MMP-9 mutation, and the authors theorised that this genetic change may have protected the patient from developing the disease’s characteristic abnormal bone formations. The āshibio team conducted additional MMP-9 gene knockout and pharmacological studies that suggested the enzyme is an attractive target for FOP, as well as other common forms of HO. The company will give further updates on its andecaliximab FOP programme at two scientific meetings this month: the FOP Drug Development Forum and the International Conference on Children’s Bone Health.New hiresMeanwhile, āshibio also announced two new members of its C-suite on Wednesday. Victoria Smith joins as chief scientific officer (CSO), and Deborah Wenkert comes on board as chief medical officer (CMO).Most recently, Smith was CSO at Amphivena Therapeutics, and earlier she served as senior director of biology at Gilead, where she was a co-inventor of andecaliximab.A paediatric rheumatologist, Wenkert has previously held the role of CMO at both Inozyme Pharma and PreciThera. She also had a five-year stint as the medical director for clinical research at Amgen.

Orphan DrugExecutive ChangeGene Therapy

20 Jun 2024

·www.biospace.com

āshibio Raises $40M in Seed and Series A Financing to Advance Therapies for Bone and Connective Tissue Disorders

- First clinical program focuses on fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder causing extra-skeletal bone formation - - Experienced leadership team poised to accelerate pipeline development with lead asset based on novel research - BRISBANE, Calif.--(BUSINESS WIRE)-- āshibio, a privately held biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, exited stealth mode today with $40 million in seed and Series A financing. The company was founded in 2022 by Chief Executive Officer Pankaj Bhargava, M.D., and the team at MPM BioImpact, where Dr. Bhargava is also an entrepreneur partner. MPM BioImpact led the Series A round, with contributing funds from Agent Capital, YK Bioventures, and Mirae Asset Venture Investment. In conjunction with the financing, Agent Capital Partner and Co-Founder Preston Noon has joined the Board of Directors. The funding will allow āshibio to continue to advance development of several investigative therapies including a potential treatment for fibrodysplasia ossificans progressiva (FOP), a rare genetic disease characterized by severe and progressive heterotopic ossification (HO), a pathological condition that causes abnormal bone formation in muscles, tendons, ligaments and other soft tissues. FOP typically starts in early childhood, is characterized by episodic and painful flare-ups, and leads to severe debilitation and shortened life span. “We are building a pipeline of innovative therapeutics that leverage emerging biology and novel mechanisms to impact bone and connective tissue disorders that have no approved treatments or where current treatment options are inadequate,” said Dr. Bhargava. “We are grateful to our investors for recognizing the promise of our approach and for supporting our development programs.” The company’s lead program is based on the discovery that the matrix metalloproteinase-9 (MMP-9) enzyme could serve as a novel target for FOP, as published in Journal of Bone and Mineral Research in February 2024. The research described the case of a unique 35-year-old patient who carries the classic genetic mutation of FOP (ACVR1 R206H, present in over 95% of patients), yet has extreme lack of heterotopic ossification (HO) and near normal mobility. The authors found that the patient has an MMP-9 mutation in addition to the FOP mutation that appears to protect him from flare-ups and the abnormal bone formation typically seen in individuals with FOP. Further studies with MMP-9 gene knockout and pharmacological experiments confirmed that MMP-9 may serve as a novel target in FOP and other more common forms of HO. āshibio licensed andecaliximab, a humanized antibody that specifically inhibits MMP-9, from Gilead Sciences, Inc. Andecaliximab has been administered to approximately 1,000 patients in previous clinical trials. āshibio plans to initiate a Phase 2/3 trial of andecaliximab in the second half of 2024 in patients with FOP. The U.S. Food and Drug Administration (FDA) designated andecaliximab an Orphan Drug for the treatment of FOP in March 2024, one month after the European Medicines Agency (EMA) issued its own Orphan Drug Designation for the therapy. The FDA also cleared āshibio's Investigational New Drug (IND) application for andecaliximab in March 2024. Experienced senior leadership team announced Prior to joining MPM BioImpact, Dr. Bhargava was the Oncology Therapeutic Area Head at Gilead Sciences. He has also held executive positions at multiple biotech companies during his career, including Sanofi and Dicerna Pharmaceuticals, where he led development programs for oncology and rare genetic diseases. In addition to completion of the Series A funding, āshibio also announced the following appointments to its senior leadership team: Victoria Smith, Ph.D., joins āshibio as Chief Scientific Officer. She has worked across several therapeutic areas including oncology, and autoimmune and inflammatory diseases. She has previously held executive or senior positions at Amphivena Therapeutics, Gilead Sciences, and Arresto Biosciences, where she was a co-inventor of andecaliximab. Deborah Wenkert, M.D., joins āshibio as Chief Medical Officer. She is an experienced pediatric rheumatologist, specializing in rare bone and connective tissue disorders, with extensive experience in both academic and industry settings. She has previously held executive or clinical development positions at Inozyme Pharma, PreciThera, and Amgen. “At āshibio, we are rapidly advancing novel therapeutics for severe and debilitating bone and connective tissue disorders, an area of great clinical need,” commented Dr. Smith. “It is extremely gratifying to be a part of such an impressive team of seasoned industry executives, clinicians, and researchers who are devoted to improving the lives of patients who have not been adequately served by currently available treatment options.” “āshibio is clearly at the forefront of drug development in heterotopic ossification and other bone and connective tissue pathologies,” added Todd Foley, managing partner at MPM BioImpact and Chair of the āshibio Board of Directors. “The company is now on a clinical path for its lead asset and is poised to advance a pipeline of programs that address unmet needs.” āshibio researchers will present an update on the andecaliximab FOP program in an oral and poster presentation at the FOP Drug Development Forum in Stockholm, Sweden on June 27-28, 2024. Company leadership will also present a poster at the International Conference on Children’s Bone Health in Salzburg, Austria from June 22-25, 2024. About āshibio āshibio is a privately held biotechnology company developing a pipeline of novel therapeutics for the treatment of bone and connective tissue disorders. Founded in 2022 by company CEO Pankaj Bhargava, M.D., and the team at MPM BioImpact, āshibio exited stealth mode in June 2024 with $40 million in Seed and Series A financing. The company plans to initiate a Phase 2/3 trial of its lead asset, andecaliximab, in the second half of 2024 in patients with fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder characterized by progressive heterotopic ossification (HO), a pathological condition characterized by abnormal bone formation in muscle and soft tissues. For more information, visit . About MPM BioImpact MPM BioImpact is a world-leading biotechnology investment firm with over 30 years of expertise creating and investing in innovative companies to deliver transformative therapies to patients. Its experienced and dedicated team of investment professionals, entrepreneurs, advisors and leading scientists translate scientific discoveries into breakthrough medicines and potential cures. For more information, visit . About Agent Capital Agent Capital is an international life sciences investment firm that supports disruptive healthcare companies focusing on novel, differentiated therapeutics and treatments that address unmet patient needs. Agent Capital aligns with scientists, entrepreneurs, and other investors to develop the next generation of healthcare innovations, leverages their industry expertise and successful track record to source premier deals, accelerate value, and drive successful exits. Since 2017, Agent Capital has invested in over 25 companies, the majority of which have executed collaborations with major pharmaceutical companies or successfully raised additional capital in the private or public markets. For more information, visit .

Orphan Drug

100 Deals associated with Andecaliximab

External Link

KEGG	Wiki	ATC	Drug Bank
D11262	-	-	DB12296

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gastroesophageal junction adenocarcinoma	Phase 3	US	Gilead Sciences, Inc.	13 Oct 2015
Gastroesophageal junction adenocarcinoma	Phase 3	AU	Gilead Sciences, Inc.	13 Oct 2015
Gastroesophageal junction adenocarcinoma	Phase 3	BE	Gilead Sciences, Inc.	13 Oct 2015
Gastroesophageal junction adenocarcinoma	Phase 3	CL	Gilead Sciences, Inc.	13 Oct 2015
Gastroesophageal junction adenocarcinoma	Phase 3	CO	Gilead Sciences, Inc.	13 Oct 2015
Gastroesophageal junction adenocarcinoma	Phase 3	CZ	Gilead Sciences, Inc.	13 Oct 2015
Gastroesophageal junction adenocarcinoma	Phase 3	FR	Gilead Sciences, Inc.	13 Oct 2015
Gastroesophageal junction adenocarcinoma	Phase 3	DE	Gilead Sciences, Inc.	13 Oct 2015
Gastroesophageal junction adenocarcinoma	Phase 3	HU	Gilead Sciences, Inc.	13 Oct 2015
Gastroesophageal junction adenocarcinoma	Phase 3	IT	Gilead Sciences, Inc.	13 Oct 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02862535 (Pubmed) Manual	Phase 1	stomach adenocarcinoma First line	16	S-1+cisplatin+andecaliximab	iqtxtrkhwd(ujxpgyktef) = Peripheral sensory neuropathy (69%), anorexia (63%), nausea (56%), and decreased neutrophil counts (44%) were the most common adverse events (AEs). ayosdoqkso (pzngiractc ) View more	Positive	30 Jun 2022
				S-1+oxaliplatin+andecaliximab
NCT02864381 (GS-US-296--2013, Pubmed \| J Immunother Cancer)	Phase 2	Advanced Gastric Adenocarcinoma	144	Andecaliximab plus Nivolumab	obhrhfllnb(qpaqyhehwb) = xtukvegkxl youstuyyzc (kinisxyxlf, 4 - 19)	Negative	01 Dec 2021
				Nivolumab alone	obhrhfllnb(qpaqyhehwb) = qsknxptxhp youstuyyzc (kinisxyxlf, 2 - 16)
GAMMA-1 (Pubmed) Manual	Phase 3	Stomach Cancer \| Gastroesophageal junction adenocarcinoma First line EGFR2 negative	432	Andecaliximab+fluorouracil	smnvhaybkc(ahmjqzioqt) = yzkdaasbwk rgwwhzfsii (qzeyerdxid ) View more	Negative	20 Mar 2021
				Placebo+fluorouracil	smnvhaybkc(ahmjqzioqt) = kqzmqxlpxz rgwwhzfsii (qzeyerdxid ) View more
NCT02862535 (phase 1b \| NCT02862535, CTgov)	Phase 1	stomach adenocarcinoma \| Gastroesophageal junction adenocarcinoma	36	Andecaliximab (Cohort 1: ADX)	ygrummmsam(klngqucant) = qznjnslhsd opmhjnhaiv (wwxcbyfnzb, dlddclxbqs - pgydzouhbe) View more	-	24 Dec 2020
				Andecaliximab+S-1+cisplatin (Cohort 2: ADX + S-1 + Cisplatin)	ygrummmsam(klngqucant) = yemisdttyy opmhjnhaiv (wwxcbyfnzb, flawelpuxe - rvqjzsjmbw) View more
NCT02864381 (GS-US-296--2013, CTgov)	Phase 2	stomach adenocarcinoma \| Gastroesophageal junction adenocarcinoma	144	Nivolumab+Andecaliximab (Andecaliximab + Nivolumab)	rlhcqyhcla(wnnwsthtlo) = bheoqfbgfi vsnvhvzccx (xxotqhvaqt, gqgufhqyaz - gatrnubkvo) View more	-	18 Sep 2020
				Nivolumab (Nivolumab)	rlhcqyhcla(wnnwsthtlo) = nffsulbtyf vsnvhvzccx (xxotqhvaqt, wdxarbfnrb - umxfrcuzsu) View more
NCT02077465 (CTgov)	Phase 1	Pulmonary Disease, Chronic Obstructive	11	Andecaliximab	mlalyqcvsx(akvzbmokaw) = gpuihftdxg ploxxjwjjm (flpaiqdglf, potyuiwpja - buphwejvkz) View more	-	13 Aug 2020
NCT02545504 (GAMMA-1, CTgov)	Phase 3	stomach adenocarcinoma \| Gastroesophageal junction adenocarcinoma	432	mFOLFOX6+Andecaliximab (Andecaliximab + mFOLFOX6)	gugxcqxqov(batfrkgxqq) = afvcevjrqd pqqpyiurol (wwjsvkxuod, hbjvqldbmk - kvtqxbjozw) View more	-	28 Apr 2020
				mFOLFOX6 (Placebo + mFOLFOX6)	gugxcqxqov(batfrkgxqq) = gqfdjjvnuz pqqpyiurol (wwjsvkxuod, fbntdgtseg - ngfgsginls) View more
NCT02862535 (ASCO_GI2019)	Phase 1	Adenocarcinoma	36	Andecaliximab 800 mg IV Q2W	fqabojuqui(ozracvqkrl) = fgzpdmomjy kdtlaaouic (pihtqzfojj )	-	29 Jan 2019
				Nivolumab plus Andecaliximab	jfecqqmdtb(bmnawouarv) = xudiqqsjaw nysjsoplsv (rbcgbnchpu ) View more
NCT02545504 (GAMMA-1, ASCO_GI2019) Manual	Phase 3	Adenocarcinoma \| HER2 negative Gastric Cancer HER2 Negative	432	mFOLFOX6+andecaliximab	wlhrymicxg(dozonrsusd) = aawxvhodke adqyheipsd (kpevvqwydw, 11.2 - 14.0) View more	Negative	17 Jan 2019
				mFOLFOX6+placebo	wlhrymicxg(dozonrsusd) = dbnpgyzoqx adqyheipsd (kpevvqwydw, 10.3 - 13.5) View more
NCT02864381 (ASCO_GI2019) Manual	Phase 2	stomach adenocarcinoma \| Gastroesophageal junction adenocarcinoma	144	nivolumab+andecaliximab	wutqqhaflx(dhmjhsbisa) = jspiuxxcuj ljtwxdnqkz (hcraauvnqn, 4.9 - 20.7) View more	Negative	17 Jan 2019
				nivolumab	wutqqhaflx(dhmjhsbisa) = oqxtqpccmk ljtwxdnqkz (hcraauvnqn, 2.3 - 15.5) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis